1P-AL-LAD

From WikiMD.com Medical Encyclopedia

1P-AL-LAD[edit | edit source]

Chemical structure of 1P-AL-LAD

1P-AL-LAD is a synthetic psychedelic compound that belongs to the lysergamide class. It is structurally related to LSD (lysergic acid diethylamide) and is known for its psychoactive effects. 1P-AL-LAD is a derivative of AL-LAD (6-allyl-6-nor-lysergic acid diethylamide) and is considered a prodrug, meaning it is metabolized in the body to produce the active compound.

Chemical Structure and Properties[edit | edit source]

1P-AL-LAD is chemically similar to other lysergamides, sharing the core structure of lysergic acid. The "1P" prefix indicates the presence of a propionyl group attached to the nitrogen at the 1-position of the indole ring. This modification is thought to influence the compound's pharmacokinetics and potency.

The molecular formula of 1P-AL-LAD is C24H29N3O2, and it has a molecular weight of 391.51 g/mol. The compound is typically synthesized in a laboratory setting and is not found naturally.

Pharmacology[edit | edit source]

1P-AL-LAD is believed to act as a partial agonist at the 5-HT2A receptor, which is the primary target for classical psychedelics. Activation of this receptor is associated with the psychedelic effects experienced by users, including altered perception, mood, and cognition.

The onset of effects typically occurs within 30 to 90 minutes after ingestion, with the peak effects lasting for 6 to 10 hours. The duration and intensity of the experience can vary based on dosage, individual metabolism, and other factors.

Effects[edit | edit source]

Users of 1P-AL-LAD report a range of effects similar to those of other psychedelics, such as LSD and psilocybin. These effects can include:

  • Visual and auditory hallucinations
  • Altered sense of time
  • Enhanced introspection
  • Emotional variability
  • Synesthesia

The subjective experience can vary widely among individuals, and the setting and mindset of the user play significant roles in shaping the experience.

Legal Status[edit | edit source]

The legal status of 1P-AL-LAD varies by country. In some jurisdictions, it is classified as a controlled substance, while in others, it may be legal or exist in a legal gray area. Users should be aware of the laws in their region before acquiring or using the compound.

Safety and Risks[edit | edit source]

As with other psychedelics, the use of 1P-AL-LAD carries potential risks, including psychological distress, anxiety, and the possibility of a "bad trip." It is important for users to approach the substance with caution, ideally in a safe and supportive environment.

Related Pages[edit | edit source]

WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD